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In past decade, type 2 diabetes (T2D) and associated metabolic complications have become a major global 
threat for human health with epidemic increase in incidence. Currently available treatments for T2D have 
several limitations and side effects making it difficult safely reach adequate metabolic control. Therefore, it 
is important to identify novel therapeutic targets for metabolic regulation, which could complement current 
treatments for T2D.  
T2D is closely associated with ectopic lipid deposition. Recent evidence suggests that hepatic lipid 
deposition is not merely a consequence of the metabolic syndrome but rather that non-alcoholic fatty liver 
disease (NAFLD), and progression to non-alcoholic steatohepatitis (NASH), exacerbate hepatic and 
systemic insulin resistance and actively contribute to the pathogenesis of the metabolic syndrome. However, 
no pharmacological treatment is approved for NAFLD/NASH, to date. 
Serine/threonine protein kinase 25 (STK25) is broadly expressed in mouse, rat and human tissues. Previous 
studies by our research group in the rat myoblast cell line L6 by small interfering RNA (siRNA) have shown 
that STK25 is involved in regulation of glucose uptake and lipid oxidation. Studies presented in this thesis 
work demonstrate that the transgenic mice overexpressing STK25 challenged with a high-fat diet display a 
shift in the metabolic balance in peripheral tissues from lipid oxidation to lipid storage, resulting in a 
systemic insulin resistance. In contrast, Stk25 knockout mice show better-preserved systemic insulin 
sensitivity via an opposite shift in the metabolic balance in peripheral tissues from lipid storage to lipid 
utilization.  
We found that STK25 coats lipid droplets in mouse liver and human hepatocytes. Our studies performed in 
mouse liver, and in hepatocytes from both mouse and human, suggest that STK25 regulates hepatic lipid 
partitioning by controlling β-oxidation and very low-density lipoprotein (VLDL)-triacylglycerol (TAG) 
secretion. Increased activity of STK25 reduces liver lipolytic capacity, which in turn results in lower 
availability of lipids for hepatic β-oxidation and VLDL-TAG secretion, leading to enhanced lipid storage. 
Upon inactivation of STK25 reciprocal increase in liver lipolytic capacity, β-oxidation and VLDL-TAG 
secretion was seen, which likely account for the reduced hepatic lipid storage. We also found a statistically 
significant positive correlation between STK25 mRNA expression in human liver biopsies and hepatic fat 
content. 
Taken together, our studies suggest that inhibition of STK25 enables the reduction of ectopic lipid 
deposition and improves insulin sensitivity and glucose utilization in peripheral tissues. Our studies 
highlight STK25 as a potential drug target for prevention and/or treatment of T2D, NAFLD and NASH. 
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